Invitae Corporation (NVTA) News
Filter NVTA News Items
NVTA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVTA News Highlights
- NVTA's 30 day story count now stands at 5.
- Over the past 17 days, the trend for NVTA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- BETS, CRSP and GENE are the most mentioned tickers in articles about NVTA.
Latest NVTA News From Around the Web
Below are the latest news stories about INVITAE CORP that investors may wish to consider to help them evaluate NVTA as an investment opportunity.
Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain StockInvitae (NVTA) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen. |
Invitae Layoffs 2023: What to Know About the Latest NVTA Job CutsInvitae layoffs are a hot topic on Friday after the genetics company announced a 15% reduction of its workforce to reduce costs. |
Why Are Chinese Stocks Up Today?Chinese stocks are up on Friday as investors react to recent economic data that includes signs of recovering in the reigon. |
Invitae Divests Ciitizen Health Data Platform and Implements Further Cost CutsInvitae (NYSE: NVTA), a leading medical genetics company, today announced strategic changes to streamline operations and reduce operating cash burn. The company has divested the assets of Ciitizen and announced strategic cost cuts, which will include a workforce reduction and other operating expense reductions. |
What Makes Invitae (NVTA) a New Buy StockInvitae (NVTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
3 Cathie Wood Stocks to Sell Before It’s Too LateThe allure of Cathie Wood Stocks investing prowess has captured a large audience of investors. Yet, even amidst all of the optimism surrounding her investment strategies, prudent investors must be aware of the potential downside risks. While some of Cathie Wood’s early bets like Tesla have paid off, many of them have lost her clients a ton of money. However, there are some Cathie Wood Stocks to sell, and these. aresome of them. Some investors may argue that her bets on revolutionary technologies |
Better Growth Stock: CRISPR Therapeutics vs. InvitaeNow is a great time to load up on growth stocks because they may be among the first to benefit in the next bull market. You'll find a lot of these candidates in the area of biotech, and two possibilities that come to mind right now are gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) and genetic-testing specialist Invitae (NYSE: NVTA). Which is the better growth stock to buy now? |
Invitae Corporation (NYSE:NVTA) Q3 2023 Earnings Call TranscriptInvitae Corporation (NYSE:NVTA) Q3 2023 Earnings Call Transcript November 8, 2023 Invitae Corporation beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.3. Operator: Good afternoon, and welcome to the Invitae Third Quarter 2023 Financial Results Conference Call. My name is Carla and I will be your operator for today’s call. We will have a […] |
Q3 2023 Invitae Corp Earnings CallQ3 2023 Invitae Corp Earnings Call |
Invitae (NVTA) Q3 2023 Earnings Call TranscriptJoining us today are president and CEO, Ken Knight; and our new CFO, Ana Schrank. Before we begin, I'd like to remind you the various remarks that we make on this call are not historical, including those about our vision and business model, future financial and operating results, future products, services, our product pipeline and the timing, expectations of future growth, reduction in burn rate and discussions with our stakeholders, and operational improvement in cost reduction efforts. |